MedPath
HSA Approval

CANDESARTAN HCT SANDOZ TABLET 16mg/12.5mg

SIN15503P

CANDESARTAN HCT SANDOZ TABLET 16mg/12.5mg

CANDESARTAN HCT SANDOZ TABLET 16mg/12.5mg

June 7, 2018

NOVARTIS (SINGAPORE) PTE LTD

SANDOZ SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD
Licence HolderSANDOZ SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET

ORAL

Medical Information

C09DA06

candesartan and diuretics

Manufacturer Information

SANDOZ SINGAPORE PTE. LTD.

Lek Pharmaceuticals d.d. (Ljubljana)

Lek Pharmaceuticals d.d. (Lendava) (Primary and Secondary Packager)

Active Ingredients

Hydrochlorothiazide

12.5mg

Hydrochlorothiazide

Candesartan cilexetil

16mg

Candesartan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

CANDESARTAN HCT SANDOZ TABLET 16mg/12.5mg - HSA Approval | MedPath